Bladder cancer in women

被引:6
作者
Baniel J. [1 ,2 ]
机构
[1] Rabin Medical Center, Petach Tikva
[2] Urology Section, Rabin Medical Center, Beilinson Campus, Petach Tikva
关键词
Bladder cancer; Transitional cell carcinoma; Vesical tumors;
D O I
10.1007/s001920050068
中图分类号
学科分类号
摘要
In women bladder cancer usually occurs above the age of 60 and comprises 3% of all female cancers. The hallmark of presentation is hematuria, which must be investigated by radiological imaging and cystoscopy. The best prognostic indicators are grade and stage. Stage divides the disease into two separate entities, superficial and invasive disease. Approximately 70%-80% of patients will present with superficial disease, 10% will fail treatment or progress to invasive disease, and 20% present with invasive disease. Superficial disease is managed by transurethral resection and additional intravesical therapy when high-risk parameters for recurrence or progression exist. Overall survival is good and the morbidity acceptable. Invasive bladder cancer carries a worse prognosis, with an average of 50% 5-year survival. Management of invasive disease warrants extensive surgery, which is the best single treatment modality. Chemotherapy and radiotherapy are implemented in the management of progression or metastasis.
引用
收藏
页码:399 / 404
页数:5
相关论文
共 59 条
[31]  
Hudson M.A., Ratliff T.L., Gillen D.P., Haaff E.O., Dresner S.M., Catalona W.J., Single course versus maintenance bacillus Calmette-Guérin therapy for superficial bladder tumors: A prospective, randomized trial, J Urol, 138, pp. 295-298, (1987)
[32]  
Badalament R.A., Herr H.W., Wong G.Y., Et al., A prospective randomized trial of maintenance versus non-maintenance intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer, J Clin Oncol, 5, pp. 441-449, (1987)
[33]  
Lamm D.L., Crawford E.D., Blumenstein B., Et al., Maintenance bacillus Calmette-Guérin immunotherapy of superficial bladder cancer: A randomized prospective Southwest Oncology Group study, J Urol, 147, 2 PART, (1992)
[34]  
Jones H.C., Swinney J., Thiotepa in the treatment of tumors of the bladder, Lancet, 2, pp. 615-616, (1961)
[35]  
Prout G.R., Koontz Jr. W.W., Coombs J., Et al., Long term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa, J Urol, 130, pp. 677-680, (1983)
[36]  
Lamm D.L., Riggs D.R., Traynelis C.L., Nseyo U.O., Apparent failure of current intra-vesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder, J Urol, 153, pp. 1444-1450, (1995)
[37]  
Morales A., Eidinger D., Bruce A.W., Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors, J Urol, 116, pp. 180-183, (1976)
[38]  
Lamm D.L., Torti F.M., Bladder cancer, 1996, CA Cancer J Clin, 46, pp. 93-112, (1996)
[39]  
Lamm D.L., Van Der Meijden A.P.M., Morales A., Et al., Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer, J Urol, 147, pp. 596-600, (1992)
[40]  
Williams R.D., Intravesical interferon alpha in the treatment of superficial bladder cancer, Semin Oncol, 15, pp. 10-13, (1988)